Bernard Lim
Director de Operaciones en CARDIOL THERAPEUTICS INC. .
Fortuna: 78 600 $ al 31/05/2024
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
David Elsley | M | - | 7 años | |
Paul Craig Mullen | M | 60 |
Anders Electronics Plc
Anders Electronics Plc Electronics DistributorsDistribution Services Anders Electronics Plc engages in wholesale of electronic and telecommunications equipment and parts. It offers display solutions, embedded solutions, and design services. The company was founded in 1952 and is headquartered in London, the United Kingdom.
Selectronic Ltd.
Selectronic Ltd. Electronic Production EquipmentElectronic Technology Selectronic Ltd. manufactures and distributes TFT displays, LED custom display lighting, touch panels, PCB modules, LED lighting and other related products. The company was founded in 1979 and is headquartered in Oxfordshire, the United Kingdom. | 8 años |
Christopher Waddick | M | - | 6 años | |
Guillermo Torre-Amione | M | - | 6 años | |
Olive O'Driscoll | F | - |
Aventamed DAC
Aventamed DAC Medical SpecialtiesHealth Technology Aventamed DAC manufactures medical devices for surgeries. The company was founded by Olive O''Driscoll and John Vaughan and is headquartered in Bishopstown, Ireland. | 11 años |
John Vaughan | M | - |
Aventamed DAC
Aventamed DAC Medical SpecialtiesHealth Technology Aventamed DAC manufactures medical devices for surgeries. The company was founded by Olive O''Driscoll and John Vaughan and is headquartered in Bishopstown, Ireland. | 11 años |
Keith E. Jansen | M | - |
Aventamed DAC
Aventamed DAC Medical SpecialtiesHealth Technology Aventamed DAC manufactures medical devices for surgeries. The company was founded by Olive O''Driscoll and John Vaughan and is headquartered in Bishopstown, Ireland. | 4 años |
Matt Holland | M | - |
Acuity Insights, Inc.
Acuity Insights, Inc. Other Consumer ServicesConsumer Services Acuity Insights, Inc. provides educational services. The company was founded by Rich Emrich, Kelly Dore, and Harold Reiter in September 2014 and is headquartered in Toronto, Canada. | - |
Christine Seng | F | - |
Threadneedle Investments Singapore (Pte) Ltd.
Threadneedle Investments Singapore (Pte) Ltd. Investment ManagersFinance Threadneedle Investments Singapore (Pte) Ltd. is an investment management firm headquartered in Singapore. They are a subsidiary of Threadneedle Asset Management Holdings Ltd., ultimately owned by Ameriprise Financial, Inc. (NYSE: AMP) in the US. The firm provides a broad range of actively managed investment strategies and solutions for individual, institutional and corporate clients in Asia. | 11 años |
Kelly Dore | M | - |
Acuity Insights, Inc.
Acuity Insights, Inc. Other Consumer ServicesConsumer Services Acuity Insights, Inc. provides educational services. The company was founded by Rich Emrich, Kelly Dore, and Harold Reiter in September 2014 and is headquartered in Toronto, Canada. | 10 años |
Briana Knowlton | F | - |
Acuity Insights, Inc.
Acuity Insights, Inc. Other Consumer ServicesConsumer Services Acuity Insights, Inc. provides educational services. The company was founded by Rich Emrich, Kelly Dore, and Harold Reiter in September 2014 and is headquartered in Toronto, Canada. | - |
Colin Stott | M | 57 | 5 años | |
Jack Patrick Cashman | M | 82 |
Aventamed DAC
Aventamed DAC Medical SpecialtiesHealth Technology Aventamed DAC manufactures medical devices for surgeries. The company was founded by Olive O''Driscoll and John Vaughan and is headquartered in Bishopstown, Ireland. | 9 años |
Jennifer Chao | F | 54 | 2 años | |
Peter Pekos | M | - | 7 años | |
Teri Loxam | F | 52 | 2 años | |
Andrea B. Parker | M | - |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | 9 años |
Paul Hudson Kidner | M | 67 |
Selectronic Ltd.
Selectronic Ltd. Electronic Production EquipmentElectronic Technology Selectronic Ltd. manufactures and distributes TFT displays, LED custom display lighting, touch panels, PCB modules, LED lighting and other related products. The company was founded in 1979 and is headquartered in Oxfordshire, the United Kingdom. | - |
Bruce Clibborn | M | - |
Aventamed DAC
Aventamed DAC Medical SpecialtiesHealth Technology Aventamed DAC manufactures medical devices for surgeries. The company was founded by Olive O''Driscoll and John Vaughan and is headquartered in Bishopstown, Ireland. | - |
Blagoja Ristevski | M | - | 9 años | |
Rick Geoffrion | M | - |
Aventamed DAC
Aventamed DAC Medical SpecialtiesHealth Technology Aventamed DAC manufactures medical devices for surgeries. The company was founded by Olive O''Driscoll and John Vaughan and is headquartered in Bishopstown, Ireland. | - |
Michael Willner | M | 57 | 3 años | |
Margaret Kato | F | - |
Anders Electronics Plc
Anders Electronics Plc Electronics DistributorsDistribution Services Anders Electronics Plc engages in wholesale of electronic and telecommunications equipment and parts. It offers display solutions, embedded solutions, and design services. The company was founded in 1952 and is headquartered in London, the United Kingdom. | - |
Thomas Moffatt | M | - | 5 años | |
Trevor Burns | M | - | 7 años | |
Kelly Narine | M | - | 4 años | |
Aidan O’Driscoll | M | - |
Aventamed DAC
Aventamed DAC Medical SpecialtiesHealth Technology Aventamed DAC manufactures medical devices for surgeries. The company was founded by Olive O''Driscoll and John Vaughan and is headquartered in Bishopstown, Ireland. | - |
Anne Tomalin | F | - | 3 años | |
Kiernan Lynch | M | 36 | - | |
Andrew Hamer | M | 62 | 3 años | |
Michael Hoey | M | - |
Front Line Medical Technologies Inc
| 6 años |
John Geddes | M | - | 2 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Eldon Smith | M | 84 | 4 años | |
Rich Emrich | M | - |
Acuity Insights, Inc.
Acuity Insights, Inc. Other Consumer ServicesConsumer Services Acuity Insights, Inc. provides educational services. The company was founded by Rich Emrich, Kelly Dore, and Harold Reiter in September 2014 and is headquartered in Toronto, Canada. | 10 años |
Iain Chalmers | M | - | 4 años | |
Deborah Brown | F | - | 3 años | |
Tan Leng Leng | F | - |
Congruix Investment Management
Congruix Investment Management Investment ManagersFinance Congruix Investment Management, formerly known as Legg Mason International Equities (Singapore), is the investment management division within Legg Mason International Equities (Singapore) Pte Ltd. which is a wholly-owned subsidiary of the Baltimore-based financial services holding company Legg Mason, Inc. (NYSE: LM). Congruix originated as Legg Mason Asset Management Asia and has been managing collective investment schemes in Singapore since 1995. Through a series of joint ventures and acquisitions, the firm has integrated Singaporean investment arms of Western Asset, Batterymarch and Rothschild Asset Management. Congruix manages and sub-advises Asia Pacific equities and mandates on behalf of institutions and retail investors, either as separate accounts or through unit trusts. Their fellow division Legg Mason Investments distributes Legg Mason's Singapore-domiciled unit trusts and Legg Mason's Luxembourg- and Dublin-domiciled mutual fund ranges. | 4 años |
Julia Ho | F | - |
Congruix Investment Management
Congruix Investment Management Investment ManagersFinance Congruix Investment Management, formerly known as Legg Mason International Equities (Singapore), is the investment management division within Legg Mason International Equities (Singapore) Pte Ltd. which is a wholly-owned subsidiary of the Baltimore-based financial services holding company Legg Mason, Inc. (NYSE: LM). Congruix originated as Legg Mason Asset Management Asia and has been managing collective investment schemes in Singapore since 1995. Through a series of joint ventures and acquisitions, the firm has integrated Singaporean investment arms of Western Asset, Batterymarch and Rothschild Asset Management. Congruix manages and sub-advises Asia Pacific equities and mandates on behalf of institutions and retail investors, either as separate accounts or through unit trusts. Their fellow division Legg Mason Investments distributes Legg Mason's Singapore-domiciled unit trusts and Legg Mason's Luxembourg- and Dublin-domiciled mutual fund ranges. | 4 años |
Jacqueline Le Saux | F | - |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | 2 años |
Soo Nam Ng | M | - |
Threadneedle Investments Singapore (Pte) Ltd.
Threadneedle Investments Singapore (Pte) Ltd. Investment ManagersFinance Threadneedle Investments Singapore (Pte) Ltd. is an investment management firm headquartered in Singapore. They are a subsidiary of Threadneedle Asset Management Holdings Ltd., ultimately owned by Ameriprise Financial, Inc. (NYSE: AMP) in the US. The firm provides a broad range of actively managed investment strategies and solutions for individual, institutional and corporate clients in Asia. | 8 años |
Jay Kleiman | M | - |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | - |
Michael Martin | M | 74 |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | - |
Wee Jia Low | M | - |
Threadneedle Investments Singapore (Pte) Ltd.
Threadneedle Investments Singapore (Pte) Ltd. Investment ManagersFinance Threadneedle Investments Singapore (Pte) Ltd. is an investment management firm headquartered in Singapore. They are a subsidiary of Threadneedle Asset Management Holdings Ltd., ultimately owned by Ameriprise Financial, Inc. (NYSE: AMP) in the US. The firm provides a broad range of actively managed investment strategies and solutions for individual, institutional and corporate clients in Asia. | 11 años |
Weixiong Liang | M | - |
Threadneedle Investments Singapore (Pte) Ltd.
Threadneedle Investments Singapore (Pte) Ltd. Investment ManagersFinance Threadneedle Investments Singapore (Pte) Ltd. is an investment management firm headquartered in Singapore. They are a subsidiary of Threadneedle Asset Management Holdings Ltd., ultimately owned by Ameriprise Financial, Inc. (NYSE: AMP) in the US. The firm provides a broad range of actively managed investment strategies and solutions for individual, institutional and corporate clients in Asia. | 6 años |
Catherine Bouchard | F | - |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | 5 años |
Gigi Chan | F | - |
Threadneedle Investments Singapore (Pte) Ltd.
Threadneedle Investments Singapore (Pte) Ltd. Investment ManagersFinance Threadneedle Investments Singapore (Pte) Ltd. is an investment management firm headquartered in Singapore. They are a subsidiary of Threadneedle Asset Management Holdings Ltd., ultimately owned by Ameriprise Financial, Inc. (NYSE: AMP) in the US. The firm provides a broad range of actively managed investment strategies and solutions for individual, institutional and corporate clients in Asia. | 13 años |
Anand Ramachandran | M | - |
Congruix Investment Management
Congruix Investment Management Investment ManagersFinance Congruix Investment Management, formerly known as Legg Mason International Equities (Singapore), is the investment management division within Legg Mason International Equities (Singapore) Pte Ltd. which is a wholly-owned subsidiary of the Baltimore-based financial services holding company Legg Mason, Inc. (NYSE: LM). Congruix originated as Legg Mason Asset Management Asia and has been managing collective investment schemes in Singapore since 1995. Through a series of joint ventures and acquisitions, the firm has integrated Singaporean investment arms of Western Asset, Batterymarch and Rothschild Asset Management. Congruix manages and sub-advises Asia Pacific equities and mandates on behalf of institutions and retail investors, either as separate accounts or through unit trusts. Their fellow division Legg Mason Investments distributes Legg Mason's Singapore-domiciled unit trusts and Legg Mason's Luxembourg- and Dublin-domiciled mutual fund ranges. | - |
Paul van Damme | M | - |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | 2 años |
Ronald M. Cresswell | M | 89 |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | - |
Chen Zhong | F | - |
Congruix Investment Management
Congruix Investment Management Investment ManagersFinance Congruix Investment Management, formerly known as Legg Mason International Equities (Singapore), is the investment management division within Legg Mason International Equities (Singapore) Pte Ltd. which is a wholly-owned subsidiary of the Baltimore-based financial services holding company Legg Mason, Inc. (NYSE: LM). Congruix originated as Legg Mason Asset Management Asia and has been managing collective investment schemes in Singapore since 1995. Through a series of joint ventures and acquisitions, the firm has integrated Singaporean investment arms of Western Asset, Batterymarch and Rothschild Asset Management. Congruix manages and sub-advises Asia Pacific equities and mandates on behalf of institutions and retail investors, either as separate accounts or through unit trusts. Their fellow division Legg Mason Investments distributes Legg Mason's Singapore-domiciled unit trusts and Legg Mason's Luxembourg- and Dublin-domiciled mutual fund ranges. | 4 años |
Nancy Chu | F | 67 |
Congruix Investment Management
Congruix Investment Management Investment ManagersFinance Congruix Investment Management, formerly known as Legg Mason International Equities (Singapore), is the investment management division within Legg Mason International Equities (Singapore) Pte Ltd. which is a wholly-owned subsidiary of the Baltimore-based financial services holding company Legg Mason, Inc. (NYSE: LM). Congruix originated as Legg Mason Asset Management Asia and has been managing collective investment schemes in Singapore since 1995. Through a series of joint ventures and acquisitions, the firm has integrated Singaporean investment arms of Western Asset, Batterymarch and Rothschild Asset Management. Congruix manages and sub-advises Asia Pacific equities and mandates on behalf of institutions and retail investors, either as separate accounts or through unit trusts. Their fellow division Legg Mason Investments distributes Legg Mason's Singapore-domiciled unit trusts and Legg Mason's Luxembourg- and Dublin-domiciled mutual fund ranges. | 4 años |
William A. Cochrane | M | 98 |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | 3 años |
André Bérard | M | 83 |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | 6 años |
Calvin Stiller | M | 83 |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | 3 años |
Surya Mohapatra | M | 74 |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | 4 años |
John C. Villforth | M | - |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | 8 años |
Xiongwei Poh | M | - |
Threadneedle Investments Singapore (Pte) Ltd.
Threadneedle Investments Singapore (Pte) Ltd. Investment ManagersFinance Threadneedle Investments Singapore (Pte) Ltd. is an investment management firm headquartered in Singapore. They are a subsidiary of Threadneedle Asset Management Holdings Ltd., ultimately owned by Ameriprise Financial, Inc. (NYSE: AMP) in the US. The firm provides a broad range of actively managed investment strategies and solutions for individual, institutional and corporate clients in Asia. | 3 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Canadá | 36 | 63.16% |
Singapur | 11 | 19.30% |
Irlanda | 7 | 12.28% |
Reino Unido | 3 | 5.26% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Bernard Lim
- Red Personal